Adventus Partners supports biotechnology and pharmaceutical companies of all sizes and stages of development, including start-ups, development-stage, and established commercial companies.

We believe in building lasting relationships that enable us to execute quickly and efficiently when client needs arise.

Value Creation Adventus

Representative Clients

(now Invivyd)
(NASDAQ: IVVD)

 
 

(NASDAQ: ALNY)
 

(NASDAQ: APGE)
 

(ASX: ALA)
 

 
 

(NASDAQ: BLUE)
 

 
 

 
 

 
 

(acquired by Organon Pharma)
 

(merged with Korro Bio)
(NASDAQ: KRRO)

 
 

 
 

 
 

(acquired by Astellas)
(NASDAQ: ISEE)

 
 

(merged with Dianthus Therapeutics)
(NASDAQ: MGTA)

 
 

 
 

(NASDAQ Copenhagen: ORPHA)
 

 
 

 
 

(NASDAQ: SYBX)
 

(acquired by Sanofi)
 

(now Repertoire Immune Medicines)
 

(NASDAQ: TCRX)
 

(NASDAQ: VSTM)
 

(NASDAQ: VYGR)
 

(now WaveBreak)